NCT05634967招募中不适用
Post-Authorization Safety Study for Assessment of Pregnancy and Infant Outcomes in Patients Treated With Kesimpta (Ofatumumab) Using OTIS Observational Pregnancy Surveillance Program and DMSKW Registry
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 725
- 试验地点
- 1
- 主要终点
- Number of participants with major structural defects
研究概览
简要总结
The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.
详细描述
The study is expected to enroll for approximately 7 years and follow the pregnant women and their infant(s) over a maximum of 21 months.
The study will be conducted as two sub-studies leveraging independent ongoing pregnancy registries:
- The Organization of Teratology Information Specialists (OTIS) Research Group, University of California, San Diego, USA (referred to as "OTIS") will serve as data source for the Kesimpta-OTIS sub-study;
- The German MS and pregnancy registry - Deutschsprachigen Multiple Sklerose und Kinderwunsch Register (DMSKW) at Katholisches Klinikum Bochum gGmbH, St Josef Hospital, Bochum, Germany (referred to as "DMSKW") will serve as data source for the Kesimpta- DMSKW sub-study.
Both registries will independently collect and assess data related to the pregnancy and infant outcomes of interest and provide aggregate data which will be further combined (metaanalyses) by Novartis (referred to as the Sponsor) or a designated contract research organization (CRO).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants must meet all the criteria listed under the respective cohorts to enroll in that particular cohort of the registry:
- •Cohort 1: Kesimpta-Exposed Cohort
- •Pregnant women
- •Diagnosed with MS, with the indication validated by medical records when possible
- •Administered Kesimpta for the treatment of MS at any time from 166 days prior to the first day of the LMP, or up to and including the end of pregnancy
- •Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants (OTIS specific), and validated developmental performance questionnaire in live born children
- •Cohort 2: Disease-Matched Comparison Cohort (Comparison Group 1)
- •Pregnant women
- •Diagnosed with MS, with the indication validated by medical records when possible
- •May or may not have taken another medication for MS in the current pregnancy
- •Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants (OTIS specific), and validated developmental performance questionnaire in live born children
- •Cohort 3: Healthy Comparison Cohort (Comparison Group 2):Kesimpta-OTIS sub-study specific
- •Pregnant women
- •Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants, and validated developmental performance questionnaire in live born children
排除标准
- •Women meeting any of the following criteria will be excluded from the cohort study:
- •Cohort 1: Kesimpta-Exposed Cohort
- •Women who have enrolled in the Kesimpta cohort study with a previous pregnancy
- •Women who have used Kesimpta for an indication other than a currently approved indication
- •Women with exposure to any of the following medications within 5 half-lives (or pharmacodynamic effect when relevant) prior to conception:
- •Other anti-CD20 monoclonal antibody: same class as Kesimpta
- •S1P modulators: same class as Mayzent
- •Cladribine (Mavenclad): Based on the US label, animal studies indicate that there is positive evidence of teratogenicity for Cladribine
- •Teriflunomide (Aubagio): The teratogenecity of teriflunomide is unknown and currently under investigation.
- •New medications (marketed after 2021) indicated for the treatment of MS will be evaluated for inclusion/exclusion criteria as the study progresses.
- •Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)
- •Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.
- •Cohort 2: Disease-Matched Comparison Cohort (Comparison Group 1)
- •Administered Kesimpta 166 days before the first day of LMP or anytime during pregnancy
- •Women with exposure to any of the following medications within 5 half-lives (or pharmacodynamic effect when relevant) of conception:
- •Anti CD-20 monoclonal antibody
- •Cladribine (Mavenclad)
- •S1P modulators
- •Teriflunomide (Aubagio) New medications (marketed after 2021) indicated for the treatment of MS will be evaluated for inclusion/exclusion criteria as the study progresses.
- •Women who have enrolled in the Kesimpta cohort or BAF312A2403 Mayzent cohort with a previous pregnancy
- •Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)
- •Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.
- •Cohort 3: Healthy Comparison Cohort (Comparison Group 2): Only applicable to Kesimpta-OTIS sub-study
- •Administered Kesimpta 166 days before or Mayzent 4 days after the first day of LMP or anytime during pregnancy
- •Women who have a diagnosis of a MS
- •Women who have a current diagnosis of any autoimmune disease
- •Women who have first contact with the project after prenatal diagnosis of any major structural defect
- •Women treated with Mayzent or Kesimpta for non-MS indication
- •Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)
- •Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.
- •Women exposed to a known human teratogenic drugs during pregnancy
结局指标
主要结局
Number of participants with major structural defects
时间窗: Up to 21 months
Number of participants with major structural defects will be collected
次要结局
- Developmental performance at approximately one year of age: Denver developmental screening test(Up to 21 months)
- Number of preterm delivery cases(Up to 21 months)
- Number of preeclampsia / eclampsia cases(Up to 21 months)
- Number of cases with pattern of 3 or more minor structural defects(Up to 21 months)
- Number of participants with postnatal growth small for age at one year of age(Up to 21 months)
- Number of elective termination cases(Up to 21 months)
- Number of participants small for gestational age(Up to 21 months)
- Developmental performance at approximately one year of age: Michaelis developmental milestones questionnaires(Up to 21 months)
- Number of serious or opportunistic infections in the first year of life.(Up to 21 months)
- Number of participants with spontaneous abortion/miscarriage(Up to 21 months)
- Number of stillbirth cases(Up to 21 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With MayzentMultiple SclerosisNCT04933552Novartis Pharmaceuticals867
招募中
不适用
Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With TildrakizumabPregnancy RelatedNCT03992729Sun Pharmaceutical Industries Limited200
招募中
不适用
Kesimpta Pregnancy and Infant Safety Study Using Real World DataMultiple SclerosisNCT06156683Novartis Pharmaceuticals1,500
已完成
不适用
Afluria Pregnancy RegistryInfluenza, HumanPregnancyBirth DefectNCT03442582Seqirus490
已完成
不适用
Flucelvax (TIVc or QIVc) Pregnancy RegistryInfluenza, HumanPregnancyBirth DefectNCT03438487Seqirus692